Nieminen H, et al. - In order to assess PHiD-CV10 (10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine) efficacy in subgroups by sex, gestational age, and birth weight, researchers performed this post-hoc analysis of a phase III/IV cluster-randomized, double-blind trial (the FinIP trial) wherein PHiD-CV10 was reported to be effective on several endpoints. In both sexes, similar effectiveness of PHiD-CV10 was evident. Premature infants vs term infants had higher incidences of pneumonia outcomes. PHiD-CV10 appeared protective in preterm infants.